| Activity of selumetinib in neurofibromatosis type 1–related plexiform neurofibromas E Dombi, A Baldwin, LJ Marcus, MJ Fisher, B Weiss, AR Kim, P Whitcomb, ... New England Journal of Medicine 375 (26), 2550-2560, 2016 | 619 | 2016 |
| Molecular determinants of response to TRAIL in killing of normal and cancer cells K Kim, MJ Fisher, SQ Xu, WS El-Deiry Clinical cancer research 6 (2), 335-346, 2000 | 559 | 2000 |
| Selumetinib in children with inoperable plexiform neurofibromas AM Gross, PL Wolters, E Dombi, A Baldwin, P Whitcomb, MJ Fisher, ... New England Journal of Medicine 382 (15), 1430-1442, 2020 | 480 | 2020 |
| An anatomic transcriptional atlas of human glioblastoma RB Puchalski, N Shah, J Miller, R Dalley, SR Nomura, JG Yoon, KA Smith, ... Science 360 (6389), 660-663, 2018 | 474 | 2018 |
| Intensive multimodality treatment for children with newly diagnosed CNS atypical teratoid rhabdoid tumor SN Chi, MA Zimmerman, X Yao, KJ Cohen, P Burger, JA Biegel, ... Journal of clinical oncology 27 (3), 385, 2009 | 452 | 2009 |
| Revised diagnostic criteria for neurofibromatosis type 1 and Legius syndrome: an international consensus recommendation E Legius, L Messiaen, P Wolkenstein, P Pancza, RA Avery, Y Berman, ... Genetics in Medicine 23 (8), 1506-1513, 2021 | 388 | 2021 |
| Selumetinib in paediatric patients with BRAF-aberrant or neurofibromatosis type 1-associated recurrent, refractory, or progressive low-grade glioma: a multicentre, phase 2 trial J Fangusaro, A Onar-Thomas, TY Poussaint, S Wu, AH Ligon, ... The lancet oncology 20 (7), 1011-1022, 2019 | 379 | 2019 |
| Visual outcomes in children with neurofibromatosis type 1–associated optic pathway glioma following chemotherapy: a multicenter retrospective analysis MJ Fisher, M Loguidice, DH Gutmann, R Listernick, RE Ferner, NJ Ullrich, ... Neuro-oncology 14 (6), 790-797, 2012 | 312 | 2012 |
| Pediatric low-grade gliomas AJ Sievert, MJ Fisher Journal of child neurology 24 (11), 1397-1408, 2009 | 299 | 2009 |
| Intermittent cyclophosphamide pulse therapy in progressive multiple sclerosis: final report of the Northeast Cooperative Multiple Sclerosis Treatment Group HL Weiner, GA Mackin, EJ Orav, DA Hafler, DM Dawson, Y LaPierre, ... Neurology 43 (5), 910-910, 1993 | 289 | 1993 |
| Nucleotide Substitution in the Ectodomain of TRAIL Receptor DR4 Is Associated with Lung Cancer and Head and Neck Cancer MJ Fisher, AK Virmani, L Wu, R Aplenc, JC Harper, SM Powell, ... Clinical cancer research 7 (6), 1688-1697, 2001 | 218 | 2001 |
| Phase II study of sorafenib in children with recurrent or progressive low-grade astrocytomas MA Karajannis, G Legault, MJ Fisher, SS Milla, KJ Cohen, JH Wisoff, ... Neuro-oncology 16 (10), 1408-1416, 2014 | 209 | 2014 |
| Optic pathway gliomas RA Avery, MJ Fisher, GT Liu Journal of Neuro-Ophthalmology 31 (3), 269-278, 2011 | 171 | 2011 |
| Objective response of multiply recurrent low‐grade gliomas to bevacizumab and irinotecan RJ Packer, R Jakacki, M Horn, B Rood, G Vezina, T MacDonald, ... Pediatric blood & cancer 52 (7), 791-795, 2009 | 166 | 2009 |
| Temozolomide in children with progressive low-grade glioma S Gururangan, MJ Fisher, JC Allen, JE Herndon, JA Quinn, DA Reardon, ... Neuro-oncology 9 (2), 161-168, 2007 | 160 | 2007 |
| Sirolimus for progressive neurofibromatosis type 1-associated plexiform neurofibromas: a neurofibromatosis clinical trials consortium phase II study [published correction … B Weiss, BC Widemann, P Wolters Neuro Oncol 17 (6), 905, 2015 | 154 | 2015 |
| Cranial irradiation increases risk of stroke in pediatric brain tumor survivors CJ Campen, SM Kranick, SE Kasner, SK Kessler, RA Zimmerman, ... Stroke 43 (11), 3035-3040, 2012 | 149 | 2012 |
| Neurocognitive outcome 12 months following cerebellar mutism syndrome in pediatric patients with medulloblastoma SL Palmer, T Hassall, K Evankovich, DJ Mabbott, M Bonner, C Deluca, ... Neuro-oncology 12 (12), 1311-1317, 2010 | 148 | 2010 |
| Pediatric low-grade gliomas: next biologically driven steps DTW Jones, MW Kieran, E Bouffet, S Alexandrescu, P Bandopadhayay, ... Neuro-oncology 20 (2), 160-173, 2018 | 143 | 2018 |
| Outcomes by clinical and molecular features in children with medulloblastoma treated with risk-adapted therapy: results of an international phase III trial (SJMB03) A Gajjar, GW Robinson, KS Smith, T Lin, TE Merchant, M Chintagumpala, ... Journal of Clinical Oncology 39 (7), 822, 2021 | 137 | 2021 |
